TABLE 2.
Univariate analysis of predictive factors of SARS‐CoV‐2‐reactive IgG antibody detection in patients without prior COVID‐19
| Allo‐SCT (n = 289) | ASCT (n = 82) | |||
|---|---|---|---|---|
| Characteristics | OR (95% CI) | p value | OR (95% CI) | p value |
| Type of vaccine, n (%) | ||||
| Moderna mRNA‐1273 vs. others | 2.06 (1.1–4.2) | .04 | 0.27 (0.03–2.2) | .23 |
| Pfizer‐BionTech BNT162b2 vs. others | 0.48 (0.2–1.01) | .055 | 1.8 (0.2–15.56) | .6 |
| Age (years) | 0.96 (0.89–1.03) | .25 | ||
| 17–30 years, n (%) | 1 | NT | ||
| 31–40 years, n (%) | 0.6 (0.17–2.09) | .4 | NT | |
| 41–50 years, n (%) | 0.6 (0.18–1.9) | .38 | NT | |
| 51–60 years, n (%) | 1.01 (0.3–3.1) | .97 | NT | |
| 61–70 years, n (%) | 0.46 (0.15–1.3) | .15 | NT | |
| >71 years, n (%) | 0.95 (0.22–4) | .9 | NT | |
| Male sex | 1.06 (0.6–1.8) | .83 | 1.2 (0.36–4.1) | .7 |
| Baseline disease | NT | |||
| AML | 1 | |||
| MDS | 0.87 (0.37–1.9) | .71 | ||
| NHL | 1.48 (0.58–3.7) | .4 | ||
| MM | 0.54 (0.12–2.4) | .42 | ||
| CLL | 0.89 (0.56–2.1) | .9 | ||
| HD | 0.81 (0.32–2) | .66 | ||
| MPN | 1.4 (0.37–5.3) | .61 | ||
| ALL | 1.2 (0.49–2.9) | .66 | ||
| Others | 1.01 (0.4–2.6) | .9 | ||
| B cell NHL vs. others | 0.15 (0.04–0.57) | .005 | ||
| Status disease at vaccination | ||||
| Complete remission | 1 | 1 | ||
| Partial remission | 1.7 (0.2–15.1) | .59 | 0.85 (0.2–3.6) | .8 |
| Not in response | 0.87 (0.2–3.4) | .87 | 0.59 (0.1–3.4) | .56 |
| Time from transplant to COVID‐19 vaccine | ||||
| <6 months | 0.05 (0.006–0.43) | .008 | 1 (0.11–9.2) | .9 |
| ≥6 month to 1 year | 0.4 (0.14–1.7) | .2 | 0.33 (0.028–4.1) | .4 |
| ≥1 year | 1 | 1 | .9 | |
| <1 year | 0.24 (0.094–0.65) | .005 | 0.72 (0.13–3.86) | .7 |
| Conditioning Regimen | NT | |||
| TBF vs. others | 0.9 (0.54–1.8) | .97 | ||
| FluBu vs. others | ||||
| Allo‐HSCT | NT | |||
| HLA identical sibling donor | 1 | |||
| URD | 0.62 (0.32–1.2) | .15 | ||
| Haplo‐identical family donor | 0.65 (0.3–1.33) | .24 | ||
| UCBT | 1.1 (0.12–10.1) | .9 | ||
| Donor/recipient HLA mismatch | 0.84 (0.46–1.5) | .57 | NT | |
| GvHD prophylaxis | NT | |||
| Post‐Cy based | 1.2 (0.69–2.09) | .5 | ||
| Sirolimus based | 1.1 (0.64–2.03) | .62 | ||
| CNI based | 1 | |||
| ATG‐based conditioning regimen | 0.96 (0.3–2.7) | .94 | NT | |
| Conditioning regimen intensity | NT | |||
| MAC | 1 | |||
| RIC | 0.93 (0.54–1.5) | .8 | ||
| IS drugs at vaccination | 0.4 (0.24–0.75) | .003 | 0.6 (0.18–2.04) | .42 |
| IS and corticosteroids | ||||
| IS and corticosteroids | 1 | 1 | ||
| IS without | 1.7 (0.6–4.8) | .3 | 4.73 (0.5–43.7) | .17 |
| None of them | 2.8 (1.03–7.6) | .04 | 3.5 (0.8–15.9) | .095 |
| Corticosteroids at vaccination | 0.34 (0.12–0.9) | .03 | 0.35 (0.1–1.1) | .08 |
| Active GvHD at vaccination | 0.56 (0.3–1.03) | .06 | NT | |
| Lenalidomide maintenance | 1.9 (0.21–16.39) | .56 | ||
| Ruxolitinib as GvHD therapy | 0.22 (0.058–0.85) | .029 | NT | |
| Blood count before vaccination (×109/ml) | ||||
| Lymphocyte count < 0.5 × 109/ml | 0.1 (0.03–0.33) | <.0001 | ||
| Lymphocyte count < 1.0 × 109/ml | 0.25 (0.12–0.4) | <.0001 | 0.5 (0.12–2.28) | .39 |
Abbreviations: ALL, acute lymphoblastic leukemia; Allo‐HSCT, allogeneic stem cell transplantation; AML means acute myeloid leukemia; ATG, anti‐thymocyte globulin; CLL, chronic lymphocytic leukemia; CNI, calcineurin inhibitor; FluBuCy, fludarabine, busulphan; GvHD, graft versus host disease; HD, Hodgkin's disease; IS, Immunosuppressors; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, chronic myeloproliferative neoplasm; NHL, non‐Hodgkin's lymphoma; NT, not tested; Post‐Cy, posttransplant cyclophosphamide; RIC, reduced‐intensity conditioning; TBF, thiotepa, fludarabine and busulphan; UCBT, umbilical cord blood transplantation; URD, adult unrelated donor.